This week’s announcement by the Corporation focused on the biology of healing confirmed that the FDA has concurred with the design of ProMetic’s design of the first of its PBI-4050's planned phase 2/3 clinical trials for Idiopathic Pulmonary Fibrosis (IPF) based on the efficacy data generated in the recently completed 40 patient Phase 2 open-label study. All patients in the study will be already receiving treatment with Boehringer-Ingelheim’ s (BI) nintedanib and further ran
20 Apr 2017
One for Roche and Boehringer-Ingelheim to watch out for!
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
One for Roche and Boehringer-Ingelheim to watch out for!
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
20 Apr 2017 -
Author:
Darshan Patel -
Pages:
7
This week’s announcement by the Corporation focused on the biology of healing confirmed that the FDA has concurred with the design of ProMetic’s design of the first of its PBI-4050's planned phase 2/3 clinical trials for Idiopathic Pulmonary Fibrosis (IPF) based on the efficacy data generated in the recently completed 40 patient Phase 2 open-label study. All patients in the study will be already receiving treatment with Boehringer-Ingelheim’ s (BI) nintedanib and further ran